Condition
Primary Invasive Breast Cancer
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Terminated2
Active Not Recruiting1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03503799Active Not RecruitingPrimary
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
NCT04016935TerminatedPrimary
EndoPredict® Extended Endocrine Trial (EXET)
NCT02794064Phase 1Completed
A Prototype Tri-modal Imaging Device for Breast Cancer
NCT00148720Phase 2Terminated
Capecitabine in Women With Operable Breast Cancer
Showing all 4 trials